FAMAR Group signed an agreement to acquire a sterile production site in Homburg (Saar), Germany, from MiP Pharma, to strengthen its footprint in high-value dosage forms and expanding its capabilities in aseptic and lyophilized fill & finish.
The Homburg facility, which has recently undergone significant investment and modernization, will become an integral part of FAMAR’s international manufacturing network. When the transaction closes, the Greek Group will operate 7 facilities across Europe.
As part of the transaction, approximately 100 employees will transfer to FAMAR. The site will be developed into a multi-customer CDMO platform, fully aligned with the company’s ambition to lead in complex and high-value pharmaceutical manufacturing.
With a legacy of 75 years of expertise, FAMAR operates in Spain, Italy, and Greece, employing over 1.850 people across a network of six production facilities and two R&D centers. FAMAR supplies a range of more than 1.700 different products for over 80 international markets.
, Germany, from MiP Pharma.){kind=link}